This article is more than 5 years old. Information may no longer be current.

FDA approves supplemental new drug application for Rescula

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Sucampo Pharmaceuticals has received approval from the U.S. Food and Drug Administration for a supplemental new drug application for Rescula to lower IOP in patients with open-angle glaucoma or ocular hypertension, according to a press release.

Rescula (unoprostone isopropyl ophthalmic solution 0.15%) is a big potassium channel activator that works by increasing the outflow of aqueous humor through the trabecular meshwork, the release said. It can be used as first-line treatment or along with other topical ophthalmic products to lower IOP.

Sucampo plans to market Rescula in the first quarter of 2013, according to the release.